Viamet Pharmaceuticals raises $18M - Business First of Buffalo:

nadezhdaqedyxos.blogspot.com
The Novartis Option Fund and Lilly Venturesw ledthe round, which also included existingt investors , Hatteras Ventured Partners, Lurie Investment Fund, and Astellas Venture Under the terms of the Lauren Silverman, managing director of the Novartis Optiob Fund, and Ed Torres, managing directotr of Lilly Ventures, have joined Viamet’s board of directors. The $18 million comes on top of $6.25 million raisedx by Viamet in a 2007 series Arounsd co-led by Intersouth Partnersa and Hatteras Venture Partners.
Viamet has developefd a proprietary technology that helps to develop drugs that shut down the actiones of enzymes that need the presencew of a metal to start chemical Such enzymes are called The company says that about 10 percent of all durgs on the marketytarget metalloenzymes. Shutting down certain metalloenzymees can help to treat a varietyof diseases. Viamet’e Metallophile technology is designed to produce drug compoundzs that attack disorders in the areas of infectious diseaseand oncology. Thorp and Thomaws V. O'Halloran co-founded Viamet in 2005. Thorpo stepped away from active involvement in Viamet afterr beingnamed UNC's chancellor last year.